2,4-Bis(1,1-dimethylethyl)oxazole | 1023292-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,4-Bis(1,1-dimethylethyl)oxazole
• 英文别名: 2,4-ditert-butyl-1,3-oxazole
• CAS: 1023292-96-7
• 化学式: C₁₁H₁₉NO
• 分子量: 181.27
• InChiKey: FKSJMQZLJLRWNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20160289212A1

  公开（公告）日：2016-10-06

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： X-A-Y-Z-L-R 1 （I） 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Selective androgen receptor modulators
  申请人：Miller Chris P.

  公开号：US20090253758A1

  公开（公告）日：2009-10-08

  This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same.

  本发明提供了公式I、Ia、Ib、Ic、Id、Ie的化合物，以及它们的盐，包含这些化合物的药物组合物和药用辅料，调节雄激素受体方法，治疗可受益于雄激素受体调节剂（例如，肌肉减少症、前列腺癌、避孕、2型糖尿病相关疾病或病症、贫血、抑郁和肾脏疾病）的疾病的方法，以及制造公式I、Ia、Ib、Ic、Id、Ie的化合物和用于制备这些化合物的中间体的过程。
• NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20170342040A1

  公开（公告）日：2017-11-30

  Novel compounds, synthesis methods and use of the same in medicine and in cosmetics are disclosed. Also disclosed, are novel compounds and ligands that modulate RARs.

  小说化合物、合成方法以及在医学和化妆品中使用这些化合物的方法被披露。还披露了调节RARs的新化合物和配体。
• SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS
  申请人：Haydon David John

  公开号：US20100298388A1

  公开（公告）日：2010-11-25

  Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ═C(H)— or ═N—; R 3 is a radical of formula -(Alk 1 ) m -(Z 1 ) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1 , Z1 is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(—O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, Or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl, or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; R 4 and R 5 are optional substituents; and R 2 , R 6 and R 7 are independently hydrogen or a radical of formula -(Alk 3 ) x -(Z 2 )y-(Alk 4 ) z -H wherein x, y and z are independently 0 or 1, Z 2 is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(—O)—, —O—(C═O)— or —C(═O)—O—; Alk 3 and Alk 4 are optionally substituted C 1 -C 3 alkylene, C 2 -C 3 alkenylene, or C 2 -C 3 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—.

  化合物的结构式（IA）或（IB）具有抗菌活性：其中W为 ═C(H)— 或 ═N—；R3为具有以下结构的基团 -(Alk1)m-(Z1)p-(Alk2)n-Q，其中m、p和n独立地为0或1，但至少m、p和n中的一个为1，Z1为—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、—N(CH2CH3)—、—C(—O)—、—O—(C═O)—、—C(═O)—O—，或者具有3至6个环原子的可选择取代的一元环碳环或杂环基团；或者具有5至10个环原子的可选择取代的二元环碳环或杂环基团；Alk1和Alk2为可选择取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可能以—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、或—N(CH2CH3)—终止或中断；Q为氢、卤素、腈基或羟基，或者具有3至6个环原子的可选择取代的一元环碳环或杂环基团；或者具有5至10个环原子的可选择取代的二元环碳环或杂环基团；R4和R5为可选取代基团；R2、R6和R7独立地为氢或具有以下结构的基团 -(Alk3)x-(Z2)y-(Alk4)z-H，其中x、y和z独立地为0或1，Z2为—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、—N(CH2CH3)—、—C(—O)—、—O—(C═O)—或—C(═O)—O—；Alk3和Alk4为可选择取代的C1-C3烷基、C2-C3烯基或C2-C3炔基基团，可能以—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—或—N(CH2CH3)—终止或中断。
• PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
  申请人：Mersana Therapeutics, Inc.

  公开号：US20170369453A1

  公开（公告）日：2017-12-28

  The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.

  本公开涉及吡咯苯并二氮杂苯并二氮杂二环己烯衍生物及其抗体药物结合物，以及使用这些结合物作为治疗和/或诊断的方法。